These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 26740513)

  • 1. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
    Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
    King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
    Polepally AR; King JR; Ding B; Shuster DL; Dumas EO; Khatri A; Chiu YL; Podsadecki TJ; Menon RM
    Clin Pharmacokinet; 2016 Aug; 55(8):1003-14. PubMed ID: 26895022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
    Menon RM; Badri PS; Wang T; Polepally AR; Zha J; Khatri A; Wang H; Hu B; Coakley EP; Podsadecki TJ; Awni WM; Dutta S
    J Hepatol; 2015 Jul; 63(1):20-9. PubMed ID: 25646891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
    King JR; Dutta S; Cohen D; Podsadecki TJ; Ding B; Awni WM; Menon RM
    Antimicrob Agents Chemother; 2016 Feb; 60(2):855-61. PubMed ID: 26596948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
    Polepally AR; Dutta S; Hu B; Podsadecki TJ; Awni WM; Menon RM
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):269-77. PubMed ID: 27310328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
    Khatri A; Menon RM; Marbury TC; Lawitz EJ; Podsadecki TJ; Mullally VM; Ding B; Awni WM; Bernstein BM; Dutta S
    J Hepatol; 2015 Oct; 63(4):805-12. PubMed ID: 26070406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
    Sulkowski MS; Eron JJ; Wyles D; Trinh R; Lalezari J; Wang C; Slim J; Bhatti L; Gathe J; Ruane PJ; Elion R; Bredeek F; Brennan R; Blick G; Khatri A; Gibbons K; Hu YB; Fredrick L; Schnell G; Pilot-Matias T; Tripathi R; Da Silva-Tillmann B; McGovern B; Campbell AL; Podsadecki T
    JAMA; 2015 Mar 24-31; 313(12):1223-31. PubMed ID: 25706092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
    Khatri A; Dutta S; Marbury TC; Preston RA; Rodrigues L; Wang H; Awni WM; Menon RM
    Clin Pharmacokinet; 2017 Feb; 56(2):153-163. PubMed ID: 27389403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
    Gamal N; Andreone P
    Drugs Today (Barc); 2015 May; 51(5):303-14. PubMed ID: 26097903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
    King JR; Menon RM
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):201-205. PubMed ID: 28263457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
    Polepally AR; Badri PS; Eckert D; Mensing S; Menon RM
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):333-339. PubMed ID: 27165046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
    Smith MA; Lim A
    Drug Des Devel Ther; 2015; 9():6083-94. PubMed ID: 26622169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.
    Flisiak R; Flisiak-Jackiewicz M
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):559-567. PubMed ID: 28317409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials.
    Polepally AR; Badri PS; Parikh A; Rodrigues L; Da Silva-Tillmann BA; Mensing S; Podsadecki TJ; Awni WM; Dutta S; Menon RM
    Antivir Ther; 2016; 21(8):707-714. PubMed ID: 27584548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
    Cattaneo D; Riva A; Clementi E; Milazzo L; Gervasoni C
    Ther Drug Monit; 2016 Jun; 38(3):285-7. PubMed ID: 26919548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
    Deeks ED
    Drugs; 2015 Jun; 75(9):1027-38. PubMed ID: 26059288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
    Cheng EY; Saab S; Holt CD; Busuttil RW
    Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
    Zha J; Ding B; Wang H; Zhao W; Yu C; Alves K; Mobashery N; Luo Y; Menon RM
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):43-52. PubMed ID: 29909549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.